A Double-Masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease. Ocul Immunol Inflamm, 15, 63-70. presented at the 03-04/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17558830. (2007).
Randomized Cinical Trial of Vitamin E in the Treatment of Uveitis-Associated Macular Edema. Am J Ophthalmol, 141, 193-194. presented at the 01/2006. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16386999. (2006).
Initial Evaluation of Subcutaneous Daclizumab Treatments for Noninfectious Uveitis: A Multicenter Noncomparative Interventional Case Series. Ophthalmology, 112, 764-770. presented at the 05/2005. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15878055. (2005).
Uveitis therapy: a phase II study using subcutaneously administered daclizumab. presented at the 2004.. (2004).
Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun, 21, 283-293. presented at the 2003.. (2003).
The use of monoclonal therapy in the treatment of intraocular inflammatory disease. presented at the 2000.. (2000).
Discontinuation of ant cytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA, 282, 1633-37. presented at the 1999.. (1999).
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proceedings of the National Academy of Science USA, 96, 7462-66. presented at the 1999.. (1999).